Oramed Pharmaceuticals (ORMP) Receives a Buy from H.C. Wainwright

By Jason Carr

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oramed Pharmaceuticals (ORMPResearch Report), with a price target of $25. The company’s shares closed on Friday at $4.15.

Selvaraju observed:

“Valuation methodology, risks and uncertainties. 15% discount rate, a 75% probability of success for ORMD-0801, and peak annual sales of roughly $2.1B (on which we project double-digit percentage royalties), we derive a total rNPV of $200M within the diabetes indication.”

According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 0.9% and a 38.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Oramed Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $15.

See today’s analyst top recommended stocks >>

Based on Oramed Pharmaceuticals’ latest earnings release for the quarter ending February 28, the company reported a quarterly GAAP net loss of $3.7 million. In comparison, last year the company had a GAAP net loss of $2.92 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.